183 related articles for article (PubMed ID: 31612573)
1. Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?
Palleschi M; Maltoni R; Sarti S; Melegari E; Bravaccini S; Rocca A
Breast J; 2020 Apr; 26(4):739-742. PubMed ID: 31612573
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
3. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
5. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Kyte JA; Røssevold A; Falk RS; Naume B
J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
[TBL] [Abstract][Full Text] [Related]
6. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Kang C; Syed YY
Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab for the treatment of breast cancer.
Reddy SM; Carroll E; Nanda R
Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
[No Abstract] [Full Text] [Related]
10. Immunotherapy in Triple-Negative Breast Cancer.
Emens LA
Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
[TBL] [Abstract][Full Text] [Related]
12. Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
Philipovskiy A; Chambers K; Konstantinidis I; McCallum R; Corral J; Gaur S
Immunotherapy; 2020 Dec; 12(18):1293-1302. PubMed ID: 32988260
[No Abstract] [Full Text] [Related]
13. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Heeke AL; Tan AR
Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
[TBL] [Abstract][Full Text] [Related]
14. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D
Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026
[TBL] [Abstract][Full Text] [Related]
15. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Torres ETR; Emens LA
Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Approaches for Breast Cancer Patients in 2023.
Emens LA; Loi S
Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
[TBL] [Abstract][Full Text] [Related]
18. Metastatic triple-negative breast cancer: Established and emerging treatments.
Puri A; Reddy TP; Patel TA; Chang JC
Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306
[TBL] [Abstract][Full Text] [Related]
19. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Kagihara JA; Andress M; Diamond JR
Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
